Mumbai, India (CU)_ The US division of Glenmark Pharmaceuticals has introduced the only approved fixed-dose combination medication for seasonal allergic rhinitis in the USA. This Ryaltris nasal spray will be marketed by the British pharmaceutical giant Hikma Pharmaceuticals. According to Brendan O’Grady, CEO of Global Formulations Business, Glenmark Pharmaceuticals, the wholesale acquisition cost price for Ryaltris will remain close to $210. He said, “Considering the co-pay mechanism until Ryaltris is covered under the insurance, patients will have to pay around $49 out of their pockets”.
In the United States, Glenmark has a new drug application for Ryaltris. The company will produce and deliver the product to Hikma, and Hikma will distribute Ryaltris in the United States. According to O’Grady, “Hikma has a strong footprint in the US as far as the nasal spray/respiratory therapeutic area is concerned. It will also allow Hikma to leverage its existing specialty sales force in the US”. According to Glenmark, nearly 24 million Americans were diagnosed with seasonal allergic rhinitis or hay fever in 2018. This covers nearly 8% (19.2 million) of adults and 7% (5.2 million) of children.
According to the research, the market size for allergic rhinitis treatments in the United States is projected to expand at a compound annual growth rate (CAGR) of 3.8% between the research period of 2018 to 2030. O’Grady said, “At present, there is only one other competing combination, which combines fluticasone propionate with azelastine hydrochloride. It is marketed in some countries by Mylan”. In addition, Glenmark has an exclusivity term of three years for this medication. He added, “In addition to the three-year exclusivity period, we also have multiple patents granted in the US, protecting Ryaltris until 2034”.
Moreover, the business based in Mumbai has also devised strategies to introduce Ryaltris to global markets. According to O’Grady, “We haven’t filed for Ryaltris in India. So far, we have launched Ryaltris in markets like Australia, the UK, Czech Republic, Poland, Italy, Ireland, South Africa, Russia, Peru, Ecuador, The Philippines and Ukraine”. He added, “Ryaltris will be launched globally, with successful launches already achieved in the countries mentioned. Ryaltris has moved towards taking a 10 per cent market share in many countries, just over a year after launch in this very congested market.”
